A double-blind, randomized, placebo-controlled, multicenter, dose-find
A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Ofatumumab
B-lymphocyte antigen CD20 binding agent
What it measured
Main measures
Cumulative number of new Gd-enhancing lesions on T1-weighted MRI from week 8 to week 24.
MRI lesions
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: 1. Patients with definite diagnosis of relapsing-remitting MS according to McDonald criteria Exclusion: Please refer to protocol for full list of exclusion criteria
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Part A: Evaluate the safety of three doses of ofatumumab in patients with relapsing remitting multiple sclerosis (RRMS).
Loading reviews and guidelines…
Related trials
- A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogeni
Phase 2 · Not yet recruiting
Still running
- Switch to Ofatumumab and Level of Immunoglobulins
Recruiting
Still running
- Non-interventional Study of Subcutaneous Ocrelizumab in Persons With R
Recruiting
Still running
- The HIt HArd and hiT Early in Multiple Sclerosis Trial
Phase 2 · Recruiting
Still running
- Brain Imaging and Immune Changes During Remibrutinib Treatment in Mult
Recruiting
Still running
- Study to Assess Effects of Ublituximab in Pediatric Participants With
Phase 2 / Phase 3 · Recruiting
Still running
History
Started
Nov 2007